VICAL--eine Perle der Biotechs !! Kurspotenzial= 561 % !!! - 500 Beiträge pro Seite

[TheReturn]

Nun sind auch Biotechnologie-Aktien in den Strudel des Hightechs-Crash geraten. Seit Jahresbeginn verlor der Nasdaq-Biotech-Index 28 Prozent. Er notiert damit rund 50 % unter seinem Höchststand vom März 2000. Die Folge: Die Aktien vieler Biotech-Firmen sind jetzt zu Ausverkaufpreisen erhältlich. Eines der kleinen, aber feinen Unternehmen dieser Branche ist der kalifornische Gen-Spezialist Vical, dessen Namen sich "Weikäl" ausspricht. Der Kurs des in San Diego beheimateten Unternehmens brauch von 69 Euro im Februar 2000 auf 11,50 Euro Mitte März dieses Jahres ein. Eine Chance für langfristig orientierte, risikobewußte Anleger. Vical besticht allerdings weder durch hohen Umsatz noch durch satte Gewinne. Der Vermögenswert sind die beeindruckenden wissenschaftlichen Leistungen. Diese Kombination macht die Vical-Aktie zwar hoch riskant - tolle Technologie kann sich über Nacht als Tollheit erweisen. Andererseits sorgen die roten Zahlen im Geschäftsbericht dafür, dass die Vical-Aktie bislang noch nicht entdeckt wurde. Mitte März kam die Firma mit gut 100 Mitarbeitern nur auf einen Börsenwert von rund 220 Millionen Euro. Allein die Barbestände in der Firmenkasse decken zwei Dritel dieser Summe ab. Vical-Chef Vijay Samant rechnet 2001 mit einem Abbau der Finanzreserven um elf bis 15 Millionen Euro. Anders gesagt: Finanziell hat Vical einen sehr langen Atem. Zentrales Element der Vical-Technologie ist die so genannte "Naked DNA" oder "nackte DNS". Das Ziel: Einzelne Gene werden in die Erbanlagen von Patienten eingeschleußt, um genetisch bedingte Krankheiten auf DNS-Ebene zu behandeln. Bisher war für dieses Einschleusen eine "Fähre"- meist ein unschädlich gemachtes Virus -nötig. Vical will ohne "Fähre" auskommen und speziell aufbereitete DNS mit aktivierten Genen oder Wirkstoffen direkt in den Körper bringen. Diese Technologien könnten eines Tages bei vielen Krankheiten zum Einsatz kommen - sie gelten als sicherer und deutlich preiswerter asl bisherige Methoden. Schon heute testet das Unternehmen seine Technologie im Rahmen von acht klinischen Studien, unter anderem bei der Behandlung von Haut-, Nieren- und Prostatakrebs. Die wichtigsten Test-Präperate sind Allovectin und Leuvectin. Daneben könnte Vicals Ansatz neue Impfstoffe gegen Infektionskrankheiten ermöglichen. So forscht der US-Pharmagigant Merck an einem HIV-Impfstoff, der unter anderem auf Vicals "Nackter DNS" aufbaut. Er wird seit 1999 am Menschen getestet. Erste Ergebnisse liegen vor; im April sollen sie veröffentlich werden. Forscher, die Merck in kleinem Kreis eingeweiht hat, geben sich optimistisch bis beeindruckt. Noch befassen sich nur wenige Analysten mit Vical. Drei Investmentbanken haben in jüngster Zeit Studien angefertigt. Sie kommen ausnahmslos zum Schluss: "Kaufen". Ähnlich sieht es Michael Fischer, Manager des Biotech-Fonds DG Lux Lacuna Apo Biotech. "Kaufen unter 20 Dollar", so sein Credo. Das entspricht einem Einstiegsniveau unter 21,70 Euro. Fischers Kursziel 76 Euro. Relativ zum Kurs im Mittte März wäre das ein sattes Plus von 561 %.

Quelle Finanzen April 2001

Ich habe mir Vical in den letzen Tagen zugelegt und setze
langfristig auf diese Aktie.
Endlich mal ein Wert der niedrig bewertet ist und viel verspricht.

Gruß
The Return.

[TheReturn]

Ja äußert sich denn keiner dazu ??


Keiner meiner Meinung ? oder anderer Meinung??

Bitte um Stellungnahmen !!!!

[flatus]

beschaeftige mich schon recht lange in Vical. Mich irritieren MASSIV die steigenden Umsaetze bei diesem kleinen Wert hier in D. Allein gestern 16 Kursfeststellungen, wo es sonst hoechstens 3 waren. Nicht, dass ich etwas dagegen haette, habe schliesslich selbst meine Maerker darin investiert.

Wenn die Aussagen des Herrn Fischer dafuer verantwortlich sein sollen, ist er bald genauso in der Kritiklinie wie Herr Foertsch. Hier koennen doch nur Kleinanleger geordert haben. die grossen gehen an die NASDAQ.

Nachfolgende News koennen wohl kaum fuer ein derartiges Interesse ausgerechnet hier in D gesorgt haben. Die Meldung enthaelt keinerlei verwertbares Zahlenwerk. Ist ja auch nur eine Vertraeglichkeitsstudie.

Nun lassen wir uns ueberraschen. Nicht, dass man mich missversteht. Freue mich natuerlich ueber jeden Kurszuwachs.

Gruss flatus

-----------

Tuesday March 27, 1:00 pm Eastern Time

Press Release

SOURCE: Vical Incorporated

Vical Announces Positive Phase I/II Results With Naked DNA
Cancer Vaccine

NEW ORLEANS, March 27 /PRNewswire/ -- Vical Incorporated (Nasdaq: VICL - news) today announced
positive safety and immunogenicity results in the Phase I/II trial of Vaxid, a patient-specific naked DNA vaccine
for low-grade, non-Hodgkin`s, B-cell lymphoma.

Stanford University investigator, John Timmerman, M.D., reported at the 92nd Annual Conference of the
American Association of Cancer Research that Vaxid was not only safe in these patients, but also generated both
cellular and humoral immune responses. Professor Ronald Levy, M.D., Chief, Division of Oncology, at
Stanford University and Principal Investigator on this trial said, ``Non-Hodgkin`s B-cell lymphoma typically
exhibits a slow growth rate and excellent initial response to current treatments. However, there is a regular pattern
of relapse to a widespread, aggressive lymphoma. It is hoped that, with further development, Vaxid may be able
to prevent or delay a relapse in some of these patients.``

The study, conducted in collaboration with the Stanford University Medical Research Center, was designed to
determine if Vaxid would produce an immune response against the patient`s B-cell lymphoma. Non-Hodgkin`s
B-cell lymphoma is a disease in which cells in the lymph nodes or other lymphatic tissue grow abnormally.

Vical President and Chief Executive Officer, Vijay Samant, remarked, ``We are pleased with the initial success
the Stanford team has achieved with Vical`s patient-specific, DNA-based cancer vaccine. These are the first
clinical results that support the potential application of Vical`s proprietary technology in the exciting field of
cancer vaccines. The results add further data to support the broad applicability of naked DNA in the areas of
therapeutic and preventive medicine.``

According to the American Cancer Society, more than 56,000 Americans are expected to be diagnosed with
non-Hodgkin`s lymphoma in 2001. It is the fifth most common cancer in the U.S., excluding non-melanoma
skin cancers. B-cell lymphoma will account for 85% of these diagnoses.

Vical Incorporated, The Naked DNA Company(TM), is focused on the development of pharmaceutical product
candidates based on its patented gene delivery technology. A number of therapeutic and vaccine product
candidates are currently under development for the prevention or treatment of cancer, infectious diseases and
metabolic disorders by Vical and its collaborative partners, including Merck & Co., Pfizer Inc., Aventis Pasteur,
Aventis Pharma, Human Genome Sciences, Centocor Inc., Merial and Boston Scientific Corporation.
Allovectin-7®, which uses a lipid-DNA complex to help the immune system recognize and attack cancer cells, is
in Phase II and Phase III testing in certain patients with metastatic melanoma and in Phase II testing in patients
with head and neck cancer. Leuvectin(TM), which uses a lipid-DNA complex to stimulate an immune response
against cancer cells, is in Phase II testing in patients with kidney cancer and prostate cancer. Vaxid, a naked DNA
vaccine to prevent relapse of B-cell lymphoma, is in Phase I/II testing. In collaboration with the National Cancer
Institute, a naked DNA vaccine to treat metastatic melanoma is in Phase I/II testing. If you are interested in any of
Vical`s clinical trials, please see our website at www.vical.com, or contact Tammy Boyce by phone at
858/646-1120 or by e-mail at [e-mail].

[TheReturn]

Ja stimmt. Aber irgendwo müssen ja die Kleinanleger odern oder?
Oder dürfen die nicht????

In den Wert muß man rein, sonst verpasst man was.

Die Aussage des Herrn Fischer finde ich ok, obwohl der
zu erwartende Kursanstieg natürlich utopisch klingt.

100% tuns ja auch oder??

[Guru-Schreck]

Tuesday April 3, 4:40 pm Eastern Time

Press Release

SOURCE: Vical Incorporated

Vical Projects Completion of Allovectin-7(R) Registration Program

SAN DIEGO, April 3 /PRNewswire/ -- Vical Incorporated (Nasdaq: VICL - news) announced today that the U.S. Food and Drug Administration
(FDA) has reconfirmed that the company`s Phase II and III trial designs could support registration of Allovectin-7® for melanoma, and that the
company expects to complete enrollment of patients in its Phase III trial in the third quarter of 2001.

Written comments received from the FDA, following a face-to-face status review meeting, reconfirmed the acceptability of the company`s registration
program to support marketing approval if the data meet the study objectives. A robust clinical outcome in one of the Phase III trial`s two endpoints,
with no detriment in the other, would be sufficient to warrant consideration for marketing approval, if the company also meets product manufacturing
and other typical regulatory requirements.

In addition, the FDA reconfirmed that the Phase II registration trial could, on its own, be the basis for marketing approval, if the data meet the clinical
endpoints. Enrollment of patients in the Phase II trial was completed in January 2001, and interim results will be presented in May at the annual meeting
of the American Society of Clinical Oncology. The FDA further confirmed that data from the Phase II trial and prior trials with Allovectin-7® would
support a submission based on Phase III trial results, assuming that the Phase III data profile is consistent with prior experience.

Vijay B. Samant, Vical`s President and Chief Executive Officer, said, ``We are pleased that the FDA has reaffirmed that our current trials could form
the basis for approval of Allovectin-7®, and excited that enrollment in our registration program is approaching completion. Everyone involved in this
program has worked long and hard to reach this point.

``We are excited that Allovectin-7® has the potential to be the first gene-based product to gain marketing approval,`` added Mr. Samant, ``and we
would consider successful commercialization as further validation of naked DNA gene delivery. Preparation for the commercial launch of Allovectin-7®
continues to be the focus of Vical`s activities.``

Registration Program

Vical`s Allovectin-7® registration program consists of two separate trials in patients with metastatic melanoma, either or both of which could lead to
registration for their respective patient populations if endpoints are achieved. The Phase II trial is designed to confirm the efficacy of Allovectin-7® in
patients with refractory (unresponsive to standard therapy) melanoma that has not yet spread to multiple internal organs. The Phase III trial is designed
to demonstrate the efficacy of Allovectin-7® when used with standard chemotherapy in patients with metastatic melanoma not previously treated with
chemotherapy.

Vical Incorporated, The Naked DNA Company(TM), is focused on the development of pharmaceutical product candidates based on its patented gene
delivery technology. A number of therapeutic and vaccine product candidates are currently under development for the prevention or treatment of
cancer, infectious diseases and metabolic disorders by Vical and its collaborative partners, including Merck & Co., Pfizer Inc., Aventis Pasteur, Aventis
Pharma, Human Genome Sciences, Centocor Inc., Merial and Boston Scientific Corporation. Allovectin-7®, which uses a lipid-DNA complex to help
the immune system recognize and attack cancer cells, is in Phase II and Phase III testing in certain patients with metastatic melanoma and in Phase II testing in patients with head and neck
cancer. Leuvectin(TM), which uses a lipid-DNA complex to stimulate an immune response against cancer cells, is in Phase II testing in patients with kidney cancer and prostate cancer.
Vaxid, a naked DNA vaccine to prevent relapse of B-cell lymphoma, is in Phase I/II testing. In collaboration with the National Cancer Institute, a naked DNA vaccine to treat metastatic
melanoma is in Phase I/II testing. If you are interested in any of Vical`s clinical trials, please see our website at www.vical.com, or contact Tammy Boyce by phone at 858/646-1120 or
by e-mail at [e-mail].

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking
statements include statements about the company`s focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product
candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product
candidates, and additional risks set forth in the company`s filings with the Securities and Exchange Commission. These forward-looking statements represent the company`s judgment as of
the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

For news releases and other information about the company, visit the Vical web site at www.vical.com.

SOURCE: Vical Incorporated